Brief: Savara Provides Regulatory Update On The MOLBREEVI* Development Program In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
06/03/2026 21:12
March 6 (Reuters) - Savara Inc SVRA.O: SAVARA PROVIDES REGULATORY UPDATE ON THE MOLBREEVI* DEVELOPMENT PROGRAM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) SAVARA - DAY 74 LETTER RECEIVED FROM U.S. FOOD AND DRUG ADMINISTRATION INDICATED AGENCY HAS NO PLANS TO CONVENE ADVISORY COMMITTEE SAVARA INC - PDUFA TARGET ACTION DATE FOR MOLBREEVI SET FOR AUGUST 22, 2026 SAVARA INC - ON TRACK TO SUBMIT MAA TO UK MHRA BY END OF Q1 2026 Source text: ID:nBw5PHRZ0a Further company coverage: SVRA.O ((Reuters.Briefs@thomsonreuters.com;))